Organogenesis Holdings Inc. (ORGO)
NASDAQ: ORGO · Real-Time Price · USD
1.415
-0.035 (-2.41%)
Sep 24, 2026, 1:10 PM EDT - Market open
Organogenesis Holdings Revenue
Organogenesis Holdings had revenue of $43.76M in the quarter ending June 30, 2026, a decrease of -56.68%. This brings the company's revenue in the last twelve months to $457.45M, up 6.50% year-over-year. In the year 2025, Organogenesis Holdings had annual revenue of $564.17M with 17.04% growth.
Revenue (ttm)
$457.45M
Revenue Growth
+6.50%
P/S Ratio
0.41
Revenue / Employee
$535,660
Employees
854
Market Cap
182.07M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 564.17M | 82.13M | 17.04% |
| Dec 31, 2024 | 482.04M | 48.90M | 11.29% |
| Dec 31, 2023 | 433.14M | -17.75M | -3.94% |
| Dec 31, 2022 | 450.89M | -16.47M | -3.52% |
| Dec 31, 2021 | 467.36M | 129.06M | 38.15% |
| Dec 31, 2020 | 338.30M | 77.32M | 29.63% |
| Dec 31, 2019 | 260.98M | 67.53M | 34.91% |
| Dec 31, 2018 | 193.45M | -5.06M | -2.55% |
| Dec 31, 2017 | 198.51M | 59.78M | 43.09% |
| Dec 31, 2016 | 138.73M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurora Cannabis | 221.16M |
| Akebia Therapeutics | 219.06M |
| Organigram Global | 217.71M |
| Lifecore Biomedical | 129.46M |
| Anika Therapeutics | 120.65M |
| ADC Therapeutics | 79.58M |
| Journey Medical | 68.18M |
| SIGA Technologies | 53.66M |
ORGO News
- 2 days ago - These beaten-down stocks could bounce back in January, if history is any guide - Market Watch
- 6 weeks ago - Organogenesis price target lowered to $2 from $3 at Truist - TheFly
- 6 weeks ago - Organogenesis Holdings Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - Organogenesis Holdings Earnings release: Q2 2026 - Filings
- 6 weeks ago - Organogenesis Holdings Quarterly report: Q2 2026 - Filings
- 6 weeks ago - Organogenesis Holdings Inc. Reports Second Quarter 2026 Financial Results - GlobeNewsWire
- 1 month ago - Organogenesis Affinity meets primary endpoint in complex venous leg ulcer trial - TheFly
- 1 month ago - Organogenesis Announces Publication of Peer-Reviewed Clinical Trial Results Demonstrating Clinical Benefit of Affinity™ in the Most Challenging and Complex Venous Leg Ulcers - GlobeNewsWire